Physician profile
Drew C Mitchell
NPI 1114547932
$2,905.91
in general payments reported to CMS, 2019-2025
13 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $591 · 2023: $1,074 · 2024: $884 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.83 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $917.46 | 2021-2024 | |
| Incyte Corporation | $425.13 | 2023-2025 | Opzelura |
| Abbvie INC. | $413.86 | 2021-2023 | |
| Pfizer INC. | $250.78 | 2022-2024 | |
| Ucb, INC. | $236.20 | 2024 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.21 | 2023 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $141.53 | 2022-2023 | Sotyktu |
| Kyowa Kirin, INC. | $111.71 | 2024 | Poteligeo |
| Janssen Biotech, INC. | $99.99 | 2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $43.07 | 2023 | |
| Amgen INC. | $21.15 | 2022 | |
| Dermavant Sciences, INC. | $16.04 | 2023 | Vtama |
| Nobelpharma America, LLC | $13.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.